Responses
Pharmacotherapy: pharmacokinetics and pharmacodynamics (including: ADE, TDM, DUE)
PHC-016 Nilotinib Versus Imatinib For the Treatment of Patients with Newly-Diagnosed Philadephia Chromosome-Positive, Chronic Myeloid Leukaemia in the Chronic Phase
Compose a Response to This Article
Other responses
No responses have been published for this article.